Enrolling
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
J1I-MC-GZBZ - ClinicalTrials.gov - NCT06260722
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i).
Enter your city or zip code to find the nearest site
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Type 2 diabetesWhat the trial is testing?
retatrutide, semaglutideCould I receive a Placebo?
NoEnrollment Goal
1250Trial Dates
Feb 21, 2024 - Mar 2027How long will I be in the trial?
The study will last about 26 months and may include up to 24 visits.Trial Phase
IIIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Be 18 years or older
Have a BMI of ≥ 25.0 kg/m^2
Have T2D
Have high blood sugar as measured by hemoglobin A1C (HbA1c 7% to 10.5%)
Participants Must Not:
Have T1D
Have had or plan to have a surgical treatment for obesity
Have history of an inflamed pancreas (pancreatitis)
Have used any weight loss drugs within the last 3 months
Have an eGFR <45 mL/min/1.73 m^2 at screening
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo